Atlas Trials

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis

Clinical trial NCT04921345 · COMPLETED

Trial details

NCT number
NCT04921345
Sponsor
Galderma R&D
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Moderate-to-Severe Atopic Dermatitis
Start date
2021-06-24
Primary completion
2025-04-28
Enrollment
109

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.